A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.

Yuan-Chin HsiehJun-Min LiaoKuo-Hsiang ChuangKai-Wen HoShih-Ting HongHui-Ju LiuBo-Cheng HuangI-Ju ChenYen-Ling LiuJaw-Yuan WangHsiang-Lin TsaiYu-Cheng SuYen-Tseng WangTian-Lu Cheng

Published in: Journal of nanobiotechnology (2022)

Our in silico V(D)J recombination platform can facilitate the development of humanized mAbs with low immunogenicity and high binding affinities. This platform can directly transform numerous mAbs with therapeutic potential to humanized or even human therapeutic Abs for clinical use.

Keyphrases

monoclonal antibody
molecular docking
dna damage
dna repair
endothelial cells
high throughput
induced pluripotent stem cells
pluripotent stem cells
dna binding
binding protein